Large-Scale Population Analysis Challenges the Current Criteria for the Molecular Diagnosis of Fascioscapulohumeral Muscular Dystrophy

Isabella Scionti,1 Francesca Greco,1 Giulia Ricci,2 Monica Govi,1 Patricia Arashiro,3 Liliana Vercelli,4 Angela Berardinelli,5 Corrado Angelini,6 Giovanni Antonini,7 Michelangelo Cao,6 Antonio Di Muzio,8 Maurizio Moggi,9 Lucia Morandi,10 Enzo Ricci,11 Carmelo Rodolico,12 Lucia Ruggiero,13 Lucio Santoro,13 Gabriele Siciliano,2 Giuliano Tomelleri,14 Carlo Pietro Trevisan,15 Giuliana Galluzzi,16 Woodring Wright,17 Mayana Zatz,18 and Rossella Tupler1,19,*

Fascioscapulohumeral muscular dystrophy (FSHD) is a common hereditary myopathy causally linked to reduced numbers (≤8) of 3.3 kilobase D4Z4 tandem repeats at 4q35. However, because individuals carrying D4Z4-reduced alleles and no FSHD and patients with FSHD and no short allele have been observed, additional markers have been proposed to support an FSHD molecular diagnosis. In particular a reduction in the number of D4Z4 elements combined with the 4A(159/161/168)PAS haplotype (which provides the possibility of expressing DUX4) is currently used as the genetic signature uniquely associated with FSHD. Here, we analyzed these DNA elements in more than 800 Italian and Brazilian samples of normal individuals unrelated to any FSHD patients. We find that 3% of healthy subjects carry alleles with a reduced number (4–8) of D4Z4 repeats on chromosome 4q and that only one-third of these alleles, 1.3%, occur in combination with the 4A161PAS haplotype. We also systematically characterized the 4q35 haplotype in 253 unrelated FSHD patients. We find that only 127 of them (50.1%) carry alleles with 1–8 D4Z4 repeats associated with 4A161PAS, whereas the remaining FSHD probands carry different haplotypes or alleles with a greater number of D4Z4 repeats. The present study shows that the current genetic signature of FSHD is a common polymorphism and that only half of FSHD probands carry this molecular signature. Our results suggest that the genetic basis of FSHD, which is remarkably heterogeneous, should be revisited, because this has important implications for genetic counseling and prenatal diagnosis of at-risk families.

Introduction

Facioscapulohumeral muscular dystrophy (FSHD [MIM 158900]), a common myopathy, has a prevalence of 1 in 20,000.1,2 The disease is characterized by weakness of selective muscle groups and wide variability of clinical expression.1,3,4 The onset of the disease is in the second or third decade of life and usually involves the weakening of facial and limb-girdle muscles. The mode of inheritance of classical FSHD is considered to be autosomal dominant, with complete penetrance by age 20.1,5 No biochemical, histological, or instrumental markers are available to independently confirm a specific FSHD diagnosis that remains mainly clinical.

The FSHD genetic defect does not reside in any protein-coding gene.6 Instead, FSHD has been genetically linked to the reduction of an integral number of tandem 3.3-kb D4Z4 repeats located on chromosome 4q35.7,8 Although nearly identical D4Z4 sequences reside on chromosome 10q26,9 only subjects with a reduced number of D4Z4 repeats on chromosome 4, but not chromosome 10, develop FSHD.10–12 Based on these results, p13E-11 EcoRI alleles larger than 50 kb (≥11 D4Z4 repeats) originating from chromosome 4 have been considered normal, whereas alleles of 35 kb or less (≤8 D4Z4 repeats) have been considered diagnostic for the disease.8,13

Because there are individuals with reduced D4Z4 alleles that do not have clinical signs of FSHD,14,15 it has been proposed that additional DNA sequences flanking the D4Z4 repeat array are necessary for disease development.16–18 These studies concluded that D4Z4 reduction is pathogenic only in a few genetic backgrounds, which include a specific simple sequence length polymorphism (SSLP) proximal to the D4Z4 repeat and the 4qA polymorphism distal to

1Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy; 2Department of Neuroscience, Neurological Clinic, University of Pisa, Pisa 56126, Italy; 3Program in Genomics, Division of Genetics, Informatics Program, Children’s Hospital, The Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA; 4Department of Neuroscience, Center for Neuromuscular Diseases, University of Turin, Turin 10126, Italy; 5Unit of Child Neurology and Psychiatry, IRCCS “C. Modino” Foundation, University of Pavia, Pavia 27100, Italy; 6Department of Neurosciences, University of Padua, Padua 35129, Italy; 7Department of Neuroscience, Salute Mentale e Organi di Senso, S. Andrea Hospital, University of Rome “Sapienza,” Rome 00189, Italy; 8Center for Neuromuscular Disease, University “G. d’Annunzio,” Chieti 66013, Italy; 9Neuromuscular Unit, IRCCS Foundation Cà Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, University of Milan, Milan 20122, Italy; 10Unit of Muscular Pathology and Immunology, Neurological Institute Foundation “Carlo Besta,” Milano 20133, Italy; 11Department of Neurosciences, Università Cattolica Policlinico A. Gemelli, Rome 00168, Italy; 12Department of Neurosciences, Psychiatry and Anaesthesiology; University of Messina, Messina 98125, Italy; 13Department of Neurological Sciences and Vision, University of Verona, Verona 37134, Italy; 14Department of Neurological and Psychiatric Sciences, University of Padua, Padua 35100, Italy; 15Molecular Genetics Laboratory of UILDM, Lazio Section, IRCCS Santa Lucia Foundation, Rome 00179, Italy; 16Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; 17Human Genome Research Center, Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, São Paulo 05508-090, Brazil; 18Program in Gene Function and Expression, University of Massachusetts Medical School, Worcester, MA 01605, USA
*Correspondence: rossella.tupler@umassmed.edu

DOI 10.1016/j.ajhg.2012.02.019. ©2012 by The American Society of Human Genetics. All rights reserved.
the repeat (Figure 1). These haplotypes, named 4A159, 4A161, and 4A168, have been proposed to be uniquely associated with FSHD. Recently it has been shown that a single-nucleotide polymorphism (SNP) in the pLAM sequence of the 4qA alleles provides a polyadenylation signal (PAS; ATTAAA) for the $\text{DUX4}$ transcript from the most distal D4Z4 unit on 4qA chromosomes. Thus, the molecular signature, named 4A(159,161,168)PAS, has been proposed to define alleles causally related to FSHD. This signature results from the combination of (1) a reduction in the number of D4Z4 elements, (2) the presence of the 4qA allele, and (3) the PAS in the pLAM sequence. In this scenario, FSHD arises from a specific genetic setting enabling the normally silent double homeobox protein 4 gene ($\text{DUX4}$ [MIM 606009]) to be expressed. On this basis, healthy subjects carrying reduced D4Z4 alleles would be explained by the absence of the 4A(159,161,168)PAS.

This model does not apply to all FSHD cases. For example, nonpenetrant carriers have been reported in FSHD families, and there are FSHD patients carrying full-length D4Z4 alleles (≥ 11 repeats) that are clinically indistinguishable from patients carrying D4Z4 alleles of reduced size (≤ 8 repeats). Rare exceptions could be explained by a variety of mechanisms that do not challenge the basic hypothesis. However, recently we found that 2.7% of cases in the Italian National Registry for FSHD (which contains over 1,100 unrelated FSHD patients) were compound heterozygotes carrying two D4Z4-reduced alleles (0.5% were homozygotes for the 4A161 haplotype). Based on this finding, we estimated that the population frequency of the 4A161PAS haplotype associated with a D4Z4-reduced allele could be higher than 1%. The correlation between genotype and phenotype in FSHD thus appears to be more complex than just the

Figure 1. Schematic Representation of Polymorphisms at the 4q and 10q Subtelomeres

(A) Schematic representation of the method used to calculate D4Z4 repeat numbers from EcoRI fragment sizes. The D4Z4 repeat array is indicated with triangles. Seven and eight D4Z4 repeats (31–36 kb EcoRI fragment size) were defined to be the upper diagnostic range for FSHD. D4Z4 repeat units on chromosomes 4 and 10 can be distinguished because all repeats on 10q contain BlnI restriction sites (B within the black triangles), whereas all D4Z4 repeats on 4q contain XapI restriction sites (X within the white triangles).

(B) Schematic representation of the current view of pathogenic haplotypes.

(C) Elements examined in the present study. In addition to the number of D4Z4 repeats, elements that distinguish subjects include: (1) the chromosomal localization of the D4Z4 repeat, chromosome 4q35 or 10q26; (2) the SSLP, which is a combination of five variable number tandem repeats, an 8 bp insertion/deletion, and two SNPs localized 3.5 kb proximal to D4Z4; it varies in length between 157 and 182 bp; (3) the AT(T/C)AAA SNP in the pLAM region; (4) a large sequence variation (termed 4qA or B) that is distal to D4Z4. In the 4qB variant, the terminal 3.3 kb repeat contains only 570 bp of a complete repeat, whereas in the 4qA variant the terminal repeat is a divergent 3.3 kb repeat named pLAM. 4q chromosomes that do not hybridize to probes for (A) and (B) are termed “null,” and their sequences vary from case to case.
presence of the 4APAS signature. In order to confirm the high frequency of this signature in the normal population and reevaluate the allele distribution in FSHD patients, we performed a systematic unbiased clinical and molecular study of 801 normal control subjects from Italy and Brazil and 253 FSHD probands from the Italian Registry for FSHD. Our results establish that the 4APAS structure is a frequent genetic polymorphism that is neither sufficient nor necessary for the development of FSHD. This result is not incompatible with evidence implicating DUX4 or other factors as important mediators of the disease. However, it does demonstrate that the pathogenesis is more complex than currently thought and that the current genetic signature is insufficient for diagnosis.

**Subjects and Methods**

**Control Population**

The control group consisted of 801 unrelated healthy subjects with no family history of muscular dystrophy. Subjects were recruited from the Italian and Brazilian populations through advertisements. Italian controls subjects were equally distributed among Northern, Central, and Southern regions. The local ethics committee approved the study. All subjects enrolled in the study were clinically and molecularly characterized after giving informed consent to participate (see Table S1 available online).

**FSHD Patients**

Two-hundred-fifty-three unrelated FSHD patients were accrued through the Italian National Registry for FSHD. All subjects were clinically and molecularly characterized. In particular, we considered patients to have typical FSHD if: (1) disease onset occurred in facial or shoulder girdle muscles; (2) there was facial and/or scapular fixator weakness; and (3) there was absence of atypical signs suggesting an alternative diagnosis (including extraocular, masticatory, pharyngeal, or lingual muscle weakness and cardiomyopathy). Clinical data were collected with the FSHD clinical form. The clinical severity of the disease was measured by summing the single scores, ranged from 0, when no signs of muscle weakness are present, to 15, when all muscle groups tested by sumiﬁed the single scores, ranged from 0, when no signs of muscle weakness are present, to 15, when all muscle groups tested are severely impaired. All selected subjects were evaluated using a standard protocol, and each subject received the standardized FSHD score previously described.

**Molecular Genetic Analysis**

DNA was prepared from isolated lymphocytes according to standard procedures. In brief, restriction endonuclease digestion of DNA was performed in agarose plugs according to the specific chromosomal background, 4A(159/161/168) PAS, allowing the expression of the DUX4 gene. An additional recent genetic criteria is that, in order to have FSHD, the reduction of D4Z4 repeats must be associated with a specific chromosomal background, 4A(159/161/168) PAS, allowing the expression of the DUX4 gene.

**Results**

**Presence of FSHD-Sized Alleles in the Healthy Population**

Previous smaller investigations of the Dutch population suggested that 3% of healthy subjects had D4Z4 alleles of 35–38 kb in size, and one-third of these might present a potentially pathogenic 4A allele. An additional genetic criteria is that, in order to have FSHD, the reduction of D4Z4 repeats must be associated with a specific chromosomal background, 4A(159/161/168) PAS, allowing the expression of the DUX4 gene. However, the frequency of compound heterozygotes in patients with FSHD suggested that the frequency of D4Z4-reduced 24–35 kb alleles associated with the 4A161PAS in the Italian population would be >1%. Because this prediction has crucial implications for clinical practice, we searched for D4Z4-reduced alleles associated with the 4A161PAS haplotype in 801 healthy individuals, DNA was performed in agarose plugs using the specific chromosomal origin of the two D4Z4-reduced alleles, DNA from each proband was analyzed by NotI digestion and hybridization with the B31 probe (Figure S1). Restriction fragment lengths were detected by autoradiography or by using a Typhoon Trio system (GE Healthcare).

4qA/4qB allelic variants were deﬁned using 7 μg of HindIII-digested DNA, PFGE electrophoresis, and Southern blot hybridization with radiolabeled 4qB and 4qA probes according to standard procedures. The 4qA/4qB variants were attributed to each chromosome on the basis of the size of EcoRI restriction fragments (Figure S1). To deﬁne the SSLP and the pLAM SNP (AT(T/C)AAA) sequences ﬂanking the D4Z4 repeat units, linear gel electrophoresis of EcoRI-digested DNA was used to isolate each D4Z4-reduced allele. The SSLP sequence was determined after PCR ampliﬁcation using speciﬁc oligonucleotides (forward primer 5'-GTTGGAGTTCTCGTTTCACGC-3' labeled with hexachlorofluorescein [HEX], reverse primer 5'-TGCAGTCTCAGGCAATGTG-3') as previously reported. Analysis of the pLAM SNP was performed on PCR-ampliﬁed DNA using speciﬁc oligonucleotides (forward primer 5'-AGCGTGCTCTGGACAACCTTG-3', reverse primer 5'-TGCGATCTCAGCGAAAAATG-3'). SSLP size differences and pLAM sequences were analyzed using an ABI Prism 3130 Genetic Analyzer.
may be permissive but is not sufficient to cause autosomal-dominant disease.

**Multiple Haplotypes Associated with FSHD**

Our observation that in the general population 1.3% of healthy subjects carry the FSHD “pathogenic” signature 4A161PAS, which enables the expression of DUX4, challenges the notion that FSHD is a fully-penetrant autosomal-dominant disorder caused by the reduction of D4Z4 repeat number associated with 4A161PAS haplotype. To test the DUX4 polyadenylation model more broadly, we systematically studied the 4q35 haplotype of 253 probands accrued through the Italian National Registry for FSHD (Table S2). The D4Z4 repeat size was systematically studied in all subjects. Table 1 shows that 204 of 253 probands (80.6%) carry D4Z4 alleles with 1–8 units, 19 (7.5%) have D4Z4 alleles with 9–10 repeats, and the remaining 30 (11.8%) show large D4Z4 alleles (>11 repeats) on both copies of chromosome 4 (Table 1). We then analyzed the 223 FSHD patients with 10 or fewer D4Z4 repeats for the presence of the 4A/B, PAS, and SSLP (see Figure 1). Only 127 FSHD probands carry the 4A161PAS haplotype associated with alleles having 1–8 D4Z4 repeats (group 1 in Figure 3). Among the remaining probands, 52 have reduced alleles associated with the 4A166PAS haplotype previously considered to not be “permissive” for FSHD disease (group 2 in Figure 3), 13 carry the 4A162PAS, 5 carry the 4A164PAS, 2 carry the 4A167PAS, 1 carries the 4A163PAS (groups 7–10 in Figure 3), and 3 bear reduced D4Z4 alleles with the 4qB polymorphism, which lacks both the pLAM region and the PAS (groups 3–4 in Figure 3). Examples of each group are reported in Figures S8–S12. Collectively, our data reveal that in our cohort of FSHD probands the SSLP allelic variants associated with D4Z4-reduced alleles differ from those previously reported (compare groups 2–10 in Figure 3 with Figure 1). This genotypic difference is also supported by the fact that we did not find the 4A168 “permissive” haplotype associated with FSHD in our population. In contrast, haplotypes considered to not be “permissive” for FSHD disease were frequent. In particular, the 4A166PAS haplotype is present associated with almost one-quarter (23.3%) of D4Z4-reduced alleles detected in our FSHD probands. More importantly, 49 of 253 FSHD probands (19%) carry alleles with more than 8 D4Z4 repeats, and only 127 (50.1%) carry D4Z4-reduced alleles associated with the 4A161PAS, the expected molecular signature for FSHD.

**Discussion**

The practice of medical genetics requires a clear, definite evaluation of the significance of mutations and/or variations of DNA sequences for diagnosis to provide prognostic information and genetic counseling. This is particularly important for a progressive disease with unpredictable...
onset and a high variability of clinical expression, such as FSHD. The extensive use over the past 20 years of DNA analysis for studying Mendelian disorders has revealed many complex mechanisms in addition to single mutant genes that cause disease. Identical phenotypes may be produced by mutations in different genes,25 the same mutation can cause different phenotypes,26 and distinct mutations in the same gene may result in different disorders that segregate with diverse Mendelian or even multifactorial patterns.27 In addition, the incomplete penetrance of certain mutations argues for the importance of modifying loci or epigenetic mechanisms influencing the clinical expression in many Mendelian disorders.28 Thus, establishing the value of mutational events underlying genetic diseases may be complex even when there are simple patterns of inheritance in diseases with a well-characterized pathologic course.

FSHD seems to fall in this complex pattern, even though it is currently considered to be a fully penetrant disease with a wide variability in clinical spectrum, ranging from subjects with very mild muscle weakness to wheelchair-bound patients.5,13 The molecular test initially used for FSHD diagnosis was based on the observation that 95% of FSHD patients carry a reduction of integral numbers of D4Z4 repeats at 4q35 with full penetrance.10 However, the wide use of this test revealed several exceptions to the original model. Through the years, the threshold size of D4Z4 alleles has been increased from the original 28 kb7 (6 repeats) to 35 kb10 (8 repeats), with FSHD cases carrying D4Z4 alleles of 38–41 kb (9–11 repeats), considered borderline alleles.22,29

Figure 3. Molecular Haplotypes of 223 Unrelated FSHD Patients
Overview of haplotypes of the D4Z4-reduced alleles (≤10 repeats) on chromosome 4 found in 223 unrelated FSHD patients. Alleles are separated into 1–3 (column 1), 4–8 (column 3), and 9–10 (column 5) D4Z4 repeat units. Within these columns, we group the observed haplotypes based on the type of SSLP and PAS. N* indicates the number of alleles found in each haplotype, and TOT(%) represents the total number of alleles found and the prevalence of each haplotype. The 4A haplotypes not previously observed in FSHD patients include 4A166 (group 2), 4A162 (group 7), 4A164 (group 8), 4A167 (group 9), and 4A163 (group 10), and the 4B haplotypes include 4B163 (group 3) and 4B166 (group 4). Frequencies of 4A161 (group 1, 63.7%) and 4A166 (group 2, 25.1%) are different than previously reported in other normal populations. Chromosomes with 4qB haplotypes (groups 3–4) lack the pLAM and PAS.

<table>
<thead>
<tr>
<th>Group 1</th>
<th>1-3 D4Z4 repeat units allele</th>
<th>N*</th>
<th>4-8 D4Z4 repeat units allele</th>
<th>N*</th>
<th>9-10 D4Z4 repeat units allele</th>
<th>N*</th>
<th>TOT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4A161PAS</td>
<td>41</td>
<td>17</td>
<td>110</td>
<td>15</td>
<td>142 (63.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4A166PAS</td>
<td>44</td>
<td>8</td>
<td>46</td>
<td>3</td>
<td>66 (26.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4B163</td>
<td>44</td>
<td>1</td>
<td>0</td>
<td>1 (0.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4B166</td>
<td>44</td>
<td>2</td>
<td>0</td>
<td>2 (0.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4A159PAS</td>
<td>44</td>
<td>0</td>
<td>0</td>
<td>1 (0.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4A162PAS</td>
<td>44</td>
<td>2</td>
<td>11</td>
<td>0</td>
<td>13 (5.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4A164PAS</td>
<td>44</td>
<td>5</td>
<td>0</td>
<td>5 (2.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4A167PAS</td>
<td>44</td>
<td>2</td>
<td>0</td>
<td>2 (0.9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4A163PAS</td>
<td>44</td>
<td>1</td>
<td>0</td>
<td>1 (0.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The American Journal of Human Genetics 90, 628–635, April 6, 2012
Additional genotype-phenotype studies led to the identification of subjects carrying D4Z4-reduced alleles with no sign of muscle weakness in FSHD families, as well as of healthy unrelated subjects without family history of FSHD. The present results from our systematic clinical and molecular analysis of FSHD patients from the Italian National Registry for FSHD, as well as a large number of healthy controls, challenge the current model for FSHD diagnosis.

Remarkably, our data establish as a general rule rather than an exception that detection of a D4Z4-reduced allele is not sufficient to diagnose FSHD. Although the majority of FSHD patients (70%) carry D4Z4 alleles with 4–8 units, this size range is carried by 3% of healthy subjects from the general population. Additionally, there is little predictive value of the 4qA161PAS haplotype in the absence of family history, because 1.3% of healthy subjects carry this haplotype, which therefore has the frequency of a common polymorphism rather than a rare mutation. Finally, 49 of 253 probands (19%) do not carry D4Z4 alleles with 1–8 repeats, and only 50% of the probands carry the A4A61 permissive haplotype.

In summary, our study indicates that a profound rethinking of the genetic disease mechanism and modes of inheritance of FSHD are now required and that entirely new models and approaches are needed. Our results do not exclude an important pathogenic role for DUX4 or other candidate factors but do establish a complex mechanism beyond current understanding. Indeed, our data point at the possibility that in the heterozygous state a D4Z4 reduction might produce a subclinical sensitized condition that requires other epigenetic mechanisms or a contributing factor to cause overt myopathy. In some rare cases, that could be by becoming homozygous and doubling the dose of a dominant factor such as DUX4. In others, it might be by the simultaneous heterozygosity for a different and recessive myopathy, as suggested by many reports in which the FSHD contractions are found in association with a second molecular defect. This possibility is also consistent with previous reports of expression changes of candidate proteins such as CRYM that were associated with FSHD in some families but that were unchanged when other families were examined. Finally, it is also plausible that drugs or toxic agents might contribute to the disease onset and clinical variability. This would explain the observation of discordant monozygotic twins carrying the FSHD reduction. It is hoped that broadening the scope of investigations, including next-generation deep sequencing in particular in families with asymptomatic and clinically affected members carrying the same FSHD allele, may finally lead to an understanding of the molecular pathogenesis of this complex disease. These findings have important clinical implications for genetic counseling of patients and families with FSHD, with particular regard to the interpretation of data in prenatal diagnosis.

Supplemental Data
Supplemental Data include twelve figures and two tables and can be found with this article online at http://www.cell.com/AJHG/.

Acknowledgments
We are indebted to all FSHD patients and their families for participating in this study. The Associazione Amici del Centro Dino Ferrari-University of Milan is gratefully acknowledged. We thank Paul D. Kaufman and Michael R. Green for their in-depth critique of the manuscript. DNA from Brazilian controls was kindly provided by Naiia Lourenço and Antonia Cerqueira (Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, Brazil). This work was supported by Telethon GUP08004 and GUP11009, by Association Francaise Contre les Myopathies 14339, by National Institute of Health-National Institutes of Neurological Disorders and Stroke grant RO1 NS047584, by Centros de Pesquisa, Inovação e Difusão/Fundação de Amparo à Pesquisa do Estado de São Paulo, by Institutos Nacionais de Ciência e Tecnologia, and by Conselho Nacional de Desenvolvimento Científico e Tecnológico.

Received: November 12, 2011
Revised: January 27, 2012
Accepted: February 16, 2012
Published online: April 4, 2012

Web Resources
The URL for data presented herein is as follows:

References
The American Journal of Human Genetics 90, 628–635, April 6, 2012


